| EMA number | EMEA/H/C/005854 |
| ATC code | J06BD06 |
| Authorisation | 12 November 2021 |
| Withdrawn | 14 April 2025 |
| Revision | 9 |
Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.